Shipra Gandhi
@gandhi_shipra
Followers
752
Following
857
Media
16
Statuses
805
Breast oncologist, translational researcher @EmoryUniversity @WinshipatEmory Tweets are my own and not medical advice.
Atlanta, GA
Joined June 2019
Spotlight Poster Discussion #1 "Racial Outcomes and Disparities" PD1-07 showing Black stage I-III breast cancer patients have worse outcomes, especially if did not attain pCR. Personalized treatment options to improve pCR desperately needed !!! @royaryam #SABCS22 @RoswellPark
1
2
27
RT @oncology_bg: Our new editorial published in @JNCI_Now where we discuss how to improve the success rates of phase 3 oncology trials. Led….
0
26
0
Generate videos in just a few seconds. Try Grok Imagine, free for a limited time.
19
15
162
RT @mirrorsmed: Timing of Recurrence After Neoadjuvant Chemo-Immunotherapy in Early-Stage Triple-Negative Breast Cancer. .
0
21
0
RT @Chrystal_Paulos: Honored to be awarded the All-Star V Foundation grant! Inspired by great team efforts between @PaulosLab @LesinskiL….
v.org
Melanoma is a serious and often deadly type of skin cancer. Although immunotherapy has saved many lives, it still doesn’t work for every patient. Our lab is developing ways to give the immune system...
0
11
0
RT @CCortiMD: Pleased to share the results of our prospective observational decision-impact study in early-stage HR+/HER2− breast cancer (N….
0
16
0
RT @WinshipAtEmory: The breast cancer session at #DDHO2025 concludes with a patient-based panel discussion and Q&A—bringing together expert….
0
2
0
RT @Neil_Iyengar: Absolutely outstanding breast cancer session at #DDHO2025. Major themes included treatment de-escalation strategies, adju….
0
5
0
RT @Chrystal_Paulos: Thanks for highlighting our @Cancer_Cell paper by amazing 1st author Anna Cole @AnnaCamille9! Props to co-1st @hknoche….
0
3
0
RT @Chrystal_Paulos: BREAKING: We uncovered a potent immune alliance that could change how we treat solid tumors. Published in @Cancer_Cell….
cell.com
Cole et al. report that adoptively transferred, tumor-specific Th17 cells engage host B cells and drive B cell proliferation and differentiation. These Th17 cells require B cells for sustained...
0
84
0
RT @NCICAPIT: Early Career Spotlight Session #4: Dr. Han Yu of @RoswellPark (DRCC U24) presents an integrated machine learning-based progn….
0
6
0
RT @WinshipAtEmory: Day 1 of #DDHO2025 concluded with the leukemia session, featuring expert panelists from Winship and @MDAndersonNews eng….
0
3
0
RT @DFCI_BreastOnc: Drs. Nancy Lin (@nlinmd) and Rebecca Dent.(@RebeccaDSing) discuss: .🔹A New Paradigm for Triple-Positive Breast Cancer?….
0
14
0
RT @HemOncToday: ☀️ New data shine light on underrepresentation of #IMGs in academic oncology leadership. 🎙️ @gandhi_shipra of @EmoryUniv….
healio.com
CHICAGO — International medical graduates are underrepresented in leadership roles at NCI-designated cancer centers, according to study results presented at ASCO Annual Meeting.Researchers also...
0
1
0
RT @Dr_ElvinaA: From ESR1 & PIK3CA-guided therapies to novel SERDs, ADCs, and CDK2 inhibitors—treatment sequencing is evolving rapidly. ✅P….
0
63
0
RT @GreatDebatesCME: Should novel endocrine backbones be used earlier in the treatment of HR+ breast cancer?. As endocrine therapies contin….
0
2
0
RT @minaam_ab: Incredibly excited to be present at #ASCO2025. -Female IMGs are underrepresented in leadership positions. -Black pts have….
0
1
0
RT @DrSGraff: A practice changing trial that IMMEDIATELY needs to be challenged. 2L TDXd only 10%, adj SOC was less than usual, and given P….
0
47
0
RT @StephenVLiu: This is a major story from #ASCO25. Randomized phase 3 trial of time of day of immunotherapy infusion. Randomized to infus….
0
490
0
RT @DrHBurstein: Cross trial comparisons are tricky. But an important point in VERITAC-2 is that its endpoint was BICR (blinded independent….
0
7
0